Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MK-4305 Improves Sleep Efficiency in PIIb: US Merck
July 5, 2010
- DSP to Enhance Its MR Support System
July 5, 2010
- Elimination of Drug Lag a Pressing Issue: New Growth Strategy
July 5, 2010
- Betaferon's Long-Term Safety Confirmed: Bayer
July 5, 2010
- Celgene's Revlimid Approved for Multiple Myeloma
July 5, 2010
- Pfizer Japan Begins Consultations in Japan Following Withdrawal of NDA for Mylotarg in US
July 5, 2010
- Actemra Effective for sJIA
July 5, 2010
- Blopress Best-Selling Drug in Japan for 6 Consecutive Years
July 5, 2010
- Astellas Applies for Mirabegron in Japan
July 5, 2010
- Gov't Should Foster More Researchers to Stimulate Drug Discovery in Japan: Lawmaker Ebata
July 5, 2010
- Japan Considers Introduction of IFRS
July 5, 2010
- Banyu/Ono Apply for Combinational Use of Sitagliptin and Alfa GI
July 5, 2010
- MBL, MCM Tie Up for Marketing of STACIA, Dedicated Reagents
July 5, 2010
- Takeda to Create Sales Subsidiary in South Korea
July 5, 2010
- Epogin SC Injection Approved
July 5, 2010
- New-Type Flu Virus Detection Kit Approved: Eiken
July 5, 2010
- Eisai Enhances Its Global Business Structure
July 5, 2010
- HP Eradication Therapy Approved for 3 Diseases
July 5, 2010
- Total Births Down by 20,000, Rising Fertility Rate Halted: 2009 Vital Statistics
July 5, 2010
- BioWa Licenses COMPLEGENT Technology to GSK
July 5, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…